お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959704

Zynteglo:新薬の洞察と市場予測 (2030年)

Zynteglo- Drug Insight and Market Forecast - 2030

出版日: 受注生産 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
Zynteglo:新薬の洞察と市場予測 (2030年)
出版日: 受注生産
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Zyntegloのブランド名で販売されているベチベロ遺伝子オートテンセルは、まれで衰弱可能性のある血液疾患の一種βサラセミアの治療薬です。Bluebird Bioによって開発され、2015年2月に米国食品医薬品局によって画期的な治療法の指定を受けました。定期的な血液が必要なβサラセミア患者に関する2つの主要な研究で、Zyntegloは輸血の必要性を減らすのに効果的であることが示されています。これらの研究では、ベータグロビンが完全に欠如しておらず、Zyntegloを投与された14人の患者のうち、11人が十分に高いレベルの赤血球を持っていたため、治療後少なくとも1年間は輸血を必要としませんでした。

当レポートでは、βサラセミアの治療薬であるZyntegloの市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020~2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。

目次

第1章 製品の概要

  • 症状
  • 作用機序
  • 用法・用量
    • 剤形と用量
  • 合成経路
  • 薬理学
    • 薬力学
    • 薬物動態
  • 副作用
  • 製品のスナップショット
  • Zyntegloの開発マイルストーン
  • 上市の詳細動向
    • 米国
    • 欧州
    • 日本
  • 特許の詳細動向

第2章 SWOT分析

  • アナリストの見解

第3章 規制のマイルストーン

  • 承認
  • 研究開発
  • 治験情報
  • 安全性・有効性
  • 製品開発活動

第4章 市場評価

  • 主要7ヶ国市場の分析
  • 米国
  • 欧州
  • 日本
  • 主な分析結果

第5章 市場参入企業

第6章 新たな治療法

第7章 付録

  • レポートの購入オプション
図表

List of Tables

  • Table 1 Zynteglo, Description
  • Table 2 Zynteglo, Trial Diversification
  • Table 3 Zynteglo, Marketed Details United States
  • Table 4 Zynteglo, Marketed Details Europe
  • Table 5 Zynteglo, Marketed Details Japan
  • Table 6 Patent Details: Zynteglo
  • Table 7 Zynteglo, Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Zynteglo
  • Table 9 Zynteglo, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Zynteglo, US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Zynteglo, EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Zynteglo, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Zynteglo, Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Zynteglo
  • Figure 2 Patent Details, Zynteglo
  • Figure 3 Zynteglo, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Zynteglo, US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Zynteglo, EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Zynteglo, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Zynteglo, Japan Market Size from 2017 to 2030 (in Millions USD)
目次
Product Code: DIDM0055

"Zynteglo- Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Zynteglo in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary:

Betibeglogene autotemcel, sold under the brand name Zynteglo, is a medication for the treatment for beta thalassemia, a rare and potentially debilitating blood disorder. It was developed by Bluebird Bio and was given breakthrough therapy designation by the U.S. Food and Drug Administration in February 2015. Zynteglo has been shown to be effective at reducing the need for blood transfusion in 2 main studies in patients with beta thalassaemia who required regular blood transfusions. In these studies, out of the 14 patients who did not completely lack beta-globin and were given Zynteglo, 11 of them had sufficiently high levels of red blood cells so that they did not need blood transfusions for at least 1 year after treatment.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Zynteglo.
  • The report contains historical and forecasted sales for Zynteglo till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Zynteglo.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Zynteglo Analytical Perspective by DelveInsight

  • In-depth Zynteglo Market Assessment

This report provides a detailed market assessment of Zynteglo in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Zynteglo Clinical Assessment

The report provides the clinical trials information of Zynteglo covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Zynteglo is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Zynteglo dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Zynteglo and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Zynteglo.
  • Our in-depth analysis of the sales data of Zynteglo from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Zynteglo in the market.

Key Questions:

  • What is the prescribed dosage and strengths of Zynteglo are available in the market?
  • What are the common adverse reactions or side effects of Zynteglo?
  • What is the product type, route of administration and mechanism of action of Zynteglo?
  • What are the chemical specifications of Zynteglo?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Zynteglo, and what is its future?
  • What are the marketed details of Zynteglo in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Zynteglo and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Zynteglo?
  • In which countries Zynteglo got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Zynteglo?
  • How the safety and efficacy results determined the approval of Zynteglo?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Zynteglo development?
  • What are the key designations that have been granted to Zynteglo?
  • What is the historical and forecasted market scenario of Zynteglo?
  • How is the market trend of Zynteglo is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Zynteglo?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Zynteglo
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.